These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3997495)

  • 1. Phenytoin bioavailability assessed by steady state serum concentrations.
    Halkin H; Gapany M; Dinai Y; Dany S
    Isr J Med Sci; 1985 Apr; 21(4):327-30. PubMed ID: 3997495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of bioavailability on the calculated Michaelis-Menten parameters of phenytoin in children.
    Koren G; Brand N; MacLeod SM
    Ther Drug Monit; 1984; 6(1):11-4. PubMed ID: 6710554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian regression analysis of non-steady-state phenytoin concentrations: evaluation of predictive performance.
    Killilea T; Coleman R; Ludden T; Peck CC; Rose D
    Ther Drug Monit; 1989; 11(4):455-62. PubMed ID: 2741195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenytoin dosage requirements and pharmacokinetic variables.
    Taylor JW; Murphy MJ; Berg MJ; Perry PJ; Lyon LW; Ludden TM
    Clin Pharm; 1983; 2(3):253-7. PubMed ID: 6883953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Phenytoin kinetics in toxic serum levels].
    Beier R; Zschiesche M; Franke G
    Psychiatr Neurol Med Psychol (Leipz); 1983 Aug; 35(8):471-8. PubMed ID: 6635035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a Bayesian regression-analysis computer program using non-steady-state phenytoin concentrations.
    Godley PJ; Ludden TM; Clementi WA; Godley SE; Ramsey RR
    Clin Pharm; 1987 Aug; 6(8):634-9. PubMed ID: 3691009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenytoin Michaelis-Menten pharmacokinetics in Saudi patients.
    el-Sayed YM; Islam SI
    Int J Clin Pharmacol Ther Toxicol; 1989 Apr; 27(4):173-8. PubMed ID: 2714918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data.
    Battino D; Croci D; Mamoli D; Messina S; Perucca E
    Epilepsy Res; 2004; 59(2-3):155-65. PubMed ID: 15246117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [NONMEM approach for estimating population pharmacokinetic parameters of phenytoin in Chinese epileptics].
    Rui JZ; Cai MH; Chu XM; Chen G
    Yao Xue Xue Bao; 1995; 30(3):172-8. PubMed ID: 7639079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability of phenytoin sodium capsules available in Thailand. Part II: In vivo study.
    Suthisisang C; Payakachat N; Chulavatnatol S; Towanabut S
    J Med Assoc Thai; 1998 Jan; 81(1):64-70. PubMed ID: 9470324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative bioavailability of 2 oral solid phenytoin dosage forms.
    Naik D; Morton DJ
    Cent Afr J Med; 1989 Apr; 35(4):384-8. PubMed ID: 2605620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition of phenytoin in critically ill trauma patients.
    Boucher BA; Rodman JH; Fabian TC; Cupit GC; Ludden TM; West ME; Ray MW
    Clin Pharm; 1987 Nov; 6(11):881-7. PubMed ID: 3677565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative approach to relative bioavailability and bioequivalence evaluation, with drugs following Michaelis-Menten elimination kinetics.
    Fagiolino P; Stareczek S
    Farmaco; 1990 Sep; 45(9):1027-36. PubMed ID: 2282123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualizing phenytoin dosage regimens using a programmable calculator.
    Ng PK
    Am J Hosp Pharm; 1980 Apr; 37(4):529-33. PubMed ID: 7377216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of sustained-release theophylline formulations.
    Bonora Regazzi M; Rondanelli R; Vidale E; Cristiani D
    Int J Clin Pharmacol Ther Toxicol; 1983 May; 21(5):245-51. PubMed ID: 6862729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
    Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
    Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative bioavailability of several phenytoin preparations marketed in Austria.
    Nitsche V; Mascher H; Schütz H
    Int J Clin Pharmacol Ther Toxicol; 1984 Feb; 22(2):104-7. PubMed ID: 6698663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum phenytoin levels with different brands.
    Kishore K; Jailakhani BL; Sharma JN; Ahuja GK
    Indian J Physiol Pharmacol; 1986; 30(2):171-6. PubMed ID: 3546122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of phenytoin: comparison between three preparations.
    Kitzes R; Ackerman Z; Levy M; Frumerman I; Shved A; Garty M
    Isr J Med Sci; 1985 Apr; 21(4):323-6. PubMed ID: 3997494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.